Post-cycle therapy after androgen abuse: A narrative review of mechanisms, evidence, and clinical perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic pooling.
PubMed 42644333 · doi:10.1530/EC-26-0319
What was done
The authors conducted a narrative review summarizing mechanisms, evidence, and clinical perspectives surrounding post-cycle therapy (PCT)—specifically selective estrogen receptor modulators, human chorionic gonadotropin, and aromatase inhibitors—used to restore hypothalamic-pituitary-gonadal (HPG) axis function following androgen abuse cessation.
What was found
The abstract reports no numerical data. It notes that spontaneous recovery of the HPG axis occurs in the majority of individuals within months after cessation. While some observational studies suggest PCT may accelerate short-term hormonal and seminal recovery, robust clinical evidence is lacking. The review outlines three perspectives: widespread unsupervised real-world use, academic non-recommendation due to uncertain risk-benefit ratios, and a pragmatic rationale for short courses in select individuals with severe symptoms or high risk of relapse.
Why it matters
This paper clarifies the major disconnect between common real-world self-treatment with PCT among androgen users and the lack of robust controlled clinical trial evidence supporting the practice.
Limits
As a narrative review, it provides no original patient data, quantitative meta-analysis, or systematic search methodology. The underlying literature is primarily observational or extrapolated from other forms of secondary hypogonadism, leaving the efficacy, safety, and necessity of PCT over spontaneous recovery unproven.
Cited by
- supports When men take exogenous testosterone, their bodies stop producing endogenous testosterone.